Janux Therapeutics Inc (JANX)

EBITDA

-$21.51M

Quarterly · Period ending: · USD

JANX logo

JANX EBITDA

Latest reported-$21.51M
JANX Quarterly EBITDA (-$1.31M → -$21.51M)
High-resolution chart · PNG

JANX ebitda history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Janux Therapeutics Inc EBITDA — Quarterly (USD)
Period endingEBITDA (USD)
-21,509,000
-23,892,000
-31,478,000
-23,812,000
-33,317,000
-22,989,000
-19,704,000
-27,549,000
-5,453,000
-14,228,000
-11,227,000
-11,068,000
-17,037,000
-17,006,000
-15,662,000
-16,447,000
-16,780,000
-13,329,000
-13,352,000
-10,739,000
-6,193,000
-2,275,000
-1,646,000
-1,255,000
-2,350,000
-1,314,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.